Expand all sections

Sirukumab

Plivensia

Extended indication Moderately to severely active Rheumatoid Arthritis (RA), second or third line after DMARD and/or bDM
Therapeutic value No judgement

Product

Active substance Sirukumab
Domain Chronic immune diseases
Main indication Rheumatism
Extended indication Moderately to severely active Rheumatoid Arthritis (RA), second or third line after DMARD and/or bDMARD (biologic), 2L, 3L.
Proprietary name Plivensia
Manufacturer Janssen
Additional remarks Registratieaanvraag ingetrokken in november 2017. Fabrikant geeft aan dat het een strategische beslissing betreft en dat alle studies zijn stopgezet.

Registration

There is currently nothing known about registration.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.